![](https://thehcdata.com/wp-content/uploads/2023/08/pexels-marc-mueller-380769.webp)
Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the “Best Emerging Technology Company” by the Octane High Tech Awards (HTA). The HTA awards recognize exceptional technology companies that have made significant contributions to their respective industries through innovation, leadership, and outstanding achievements.
During the initial judging session, the HTA team was impressed by Immunis’ groundbreaking advancements in the development of cellular secretome therapies for people with muscle atrophy associated with knee osteoarthritis (KOA). One of the most pressing challenges for individuals with KOA is regaining lost muscle mass and improving muscle function to help offset knee pain and stiffness. As there are currently no clinical treatments for mitigating muscle loss, Immunis’ cutting-edge secretome therapeutics push the envelope of healthcare technology in the hope of driving positive outcomes for KOA patients.
Immunis was one of the few companies that advanced to the final HTA judging round. In early August, HTA judges interviewed Immunis’ Chief Business Officer, Mark Cabato, after which they named Immunis an award finalist. The winners will be announced during the exclusive HTA ceremony in September.
Selecting Immunis as a finalist is a testament to the groundbreaking work and dedication of our talented team in developing cutting-edge technologies that have the potential to revolutionize healthcare. This recognition comes as a great honor to Immunis and reinforces our commitment to improving the lives of people around the world through our transformative, investigational secretome products.
Source: https://www.businesswire.com/